<DOC>
	<DOC>NCT01194986</DOC>
	<brief_summary>The purpose of this study is to investigate features of radioligand [11C]AZ12807110 and how much AZD5213 displaces radioligand from histamine receptors when given together.</brief_summary>
	<brief_title>Evaluation of Histamine H3 Receptor Radioligand [11C]AZ12807110 and Histamine H3 Receptor Occupancy of AZD5213 After Oral Administration</brief_title>
	<detailed_description />
	<mesh_term>Histamine</mesh_term>
	<mesh_term>Histamine phosphate</mesh_term>
	<criteria>Healthy male and/or female volunteers between 20 to 45 years with suitable veins for cannulation or repeated venipuncture (pilot panel) Female must be of nonchild bearing potential (pilot panel) BMI between 18 to 30 30 kg/m2 Normal MRI scan Provision of signed, written and dated informed consent History of any clinically significant disease or disorder History or presence of gastrointestinal, hepatic or renal disease Prolonged QTcF &gt;450 ms or shortened QTcF &lt;340 ms or family history of long QT syndrome History of severe allergy or hypersensitivity or ongoing allergy or hypersensitivity Healthy volunteer suffers from claustrophobia</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Receptor binding</keyword>
	<keyword>Histamine H3 receptor</keyword>
	<keyword>binding</keyword>
	<keyword>radioligand</keyword>
</DOC>